Ongoing Clinical Trials for Gouty Arthritis
Currently, there is 1 ongoing clinical trial investigating treatment strategies for gouty arthritis. This trial is being conducted in the Netherlands and focuses on comparing different approaches to managing urate-lowering therapy in patients whose gout is in remission. The study examines whether continuing or stopping medications that reduce uric acid levels is more effective for maintaining long-term remission.
Clinical trial locations
Study on Gout Treatment: Comparing Allopurinol, Benzbromarone, and Febuxostat in Patients with Gout in Remission
This trial is designed to help doctors understand the best way to manage treatment in patients whose gout is well controlled. The study focuses on a critical question: should patients continue taking urate-lowering medications after achieving remission, or is it safe to stop?
Main inclusion criteria:
- Patients must have a confirmed diagnosis of gout, a type of arthritis that causes sudden, severe pain and swelling in the joints
- They must be currently using urate-lowering therapy such as allopurinol, benzbromarone, or febuxostat
- Patients should have been in remission for at least 12 months, meaning no sudden gout attacks or visible lumps caused by uric acid crystals under the skin
- Their uric acid levels in the blood must be 0.36 mmol/l or lower and have remained at this level for the past 12 months
- Pain related to gout should be less than 2 on a scale of 0 to 10, where 0 means no pain
- Patients must be 18 years or older and able to provide informed consent
Main exclusion criteria:
- Patients with a joint condition other than gout cannot participate
- Those outside the specified age range are not eligible
- Patients considered vulnerable and needing special protection cannot join the study
- Anyone who does not meet the specific health requirements set by the study is excluded
Focus and goals:
The study will last for 24 months and will compare two different strategies. Participants will be randomly assigned to either continue their current urate-lowering medication or to stop taking it. The main goal is to determine which approach is better at maintaining remission during the final six months of the study. Remission is defined as having no gout attacks, no visible uric acid deposits, and minimal pain.
During the trial, researchers will carefully monitor participants to see if they continue to meet the criteria for remission. They will look at whether patients experience any gout attacks, develop new tophi, or have increased pain levels. The study will also evaluate the cost-effectiveness of both strategies, examining the balance between treatment benefits and associated costs.
Investigational drugs:
The medications being studied are allopurinol, benzbromarone, and febuxostat. These are all urate-lowering therapies taken orally that work to reduce uric acid levels in the blood. Allopurinol works by blocking an enzyme called xanthine oxidase, which is responsible for producing uric acid in the body. By reducing uric acid levels, these medications help prevent gout attacks and the formation of painful deposits under the skin.
Summary
This single ongoing trial represents an important investigation into the long-term management of gouty arthritis. Conducted in the Netherlands, it addresses a practical question that many patients and doctors face: whether it is safe to stop urate-lowering therapy once remission has been achieved and maintained for a significant period.
The trial’s focus on three commonly used medications—allopurinol, benzbromarone, and febuxostat—provides valuable insights into real-world treatment scenarios. By comparing the strategy of continuing versus stopping therapy, the study aims to provide evidence-based guidance that could improve quality of life for patients while potentially reducing unnecessary medication use and associated costs.
Patients interested in this trial should note that eligibility requires having maintained stable remission for at least 12 months with well-controlled uric acid levels. The 24-month duration allows for thorough monitoring of long-term outcomes, which is essential for understanding the sustainability of remission after treatment changes.